Ziad M.
- Country
- France
- Department
- Néphrologie
Research Overview
- Efficacy and Safety Evaluation of Inaxaplin (VX-147) in APOL1-Mediated Proteinuric Kidney Disease: A Phase 2/3 Adaptive, Double-Blind, Placebo-Controlled Study
- Evaluation of Rituximab for Relapse Prevention in Adult Minimal Change Nephrotic Syndrome: A Randomized Controlled Trial
- Evaluation of Nicotinamide Efficacy and Tolerance in Patients with Persistent Acute Kidney Injury: A Randomized Double-Blind Controlled Trial
Data & Insights
Has run more than one trial at 5 of 27 partner sites.
Specializations
Kidney Disease Research
This investigator specializes in APOL1-mediated proteinuric kidney disease, conducting innovative therapeutic research to advance treatment options for patients with genetic kidney disorders.
- Proteinuric Kidney Conditions
- Genetic Kidney Disorders
- APOL1-Related Nephropathy
The research encompasses evaluation of novel therapeutic approaches for managing protein-mediated kidney dysfunction.
Cardiovascular Nephrology
The investigator focuses on atherosclerotic cardiovascular disease in patients with end-stage kidney disease, particularly studying interventions for dialysis patients.
- Cardiovascular Complications in ESKD
- Dialysis-Related Research
- Inflammatory Markers in Kidney Disease
The research addresses the intersection of cardiovascular and renal health in advanced kidney disease patients.
Nephrotic Syndrome Treatment
Research interests include therapeutic approaches for minimal change nephrotic syndrome, focusing on innovative treatment protocols for adult patients.
- Adult Nephrotic Syndrome
- Relapse Prevention Strategies
- Immunological Interventions
The investigator explores treatment modalities for managing nephrotic syndrome and preventing disease recurrence.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.